All three companies are early-stage biotechnology companies working on next-generation therapeutics with advanced ...

Pluvicto, Novartis’ blockbuster radiopharmaceutical for prostate cancer, has been greenlighted by the FDA for use earlier in ...

Congress Wealth Management LLC DE purchased a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) in the 4th ...

Corient Private Wealth LLC lessened its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 4.0% during the ...

After a 6-year run, CRISPR Therapeutics COO Julianne Bruno is stepping out the door to pursue other opportunities. Bruno's ...

What’s really exciting about gene editing is precision and speed, says Pairwise cofounder and CEO Tom Adams, PhD.

Spread the love Introduction The biotechnology industry continues to be at the forefront of scientific innovation, driving ...

Genomics encompasses the study of a complete set of genes, their work process, and their way of interacting with each other and the environment. While it incorporates elements of genetics, the primary ...

Learn more about whether Alvotech or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which ...

Full study results are expected in June 2025, but early results demonstrate strong potential; 60% of trial patients experienced full or partial lesion clearance Torqur AG, an innovative clinical ...

The therapy, EPI-321, is intended to treat cases of facioscapulohumeral muscular dystrophy, a genetic neuromuscular disorder.

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases ...